Market Scenario:
Ventilator-associated pneumonia is a type of lung infection caused to patients who are on ventilators. Ventilator-associated pneumonia is caused mainly due to lung disease, neurologic disease, and trauma to critically ill persons. Diagnosing VAP requires aggressive surveillance combined with the radiographic examination, bedside examination, and microbiologic examinations of respiratory secretions. Growing Intensive Care Unit Admissions due to rising prevalence of respiratory diseases, rising number of ICU beds and high incidence of traumatic injuries provides favorable backgrounds for the market to grow. According to CDC in 2013, there were 2.8 million traumatic brain injury visits to emergency department and hospitals. The emergency department visits of brain injury patients increased by 47% from 2007. Thus, increasing incidence of TBI drives the growth of the market. Furthermore, increasing geriatric population is likely to fuel the market to grow. According to the U.S. Census Bureau in 2015, 47.8 million people were 65 years or older, and in 2060, 98.2 million are expected to be 65 years or older. Such increasing trend in the geriatric population provides favorable backgrounds for the market to grow.
Segmentation
The global Ventilator-associated pneumonia market is segmented on the basis of diagnosis, mode of treatment, and end-user. The Ventilator-associated pneumonia market, by diagnosis categorized into Clinical Examination, Radiological Examination, Microbiological Analysis and others. Microbiological Analysis is further sub-segmented into Blood and pleural fluid cultures, Nonquantitative or semi-quantitative airway sampling and Quantitative cultures of airway specimens. Mode of treatment segment is segmented into Homecare, Hospital care, and others. On the basis of end-user, the market is segmented into Hospitals & Clinics, Research centers, Ambulatory Care Centers and Emergency Medical Services (EMS).
Regional Analysis
Globally, Ventilator-associated pneumonia (VAP) market consists of four regions Americas, Europe, Asia Pacific and Middle East & Africa. America is the largest market for Ventilator-associated pneumonia (VAP) whose growth is contributed to increase in prevalence of smoking leading to lung diseases, large number of patients suffering from chronic heart diseases and demand of mechanical ventilators. The market is growing continuously in Europe due to extensive demand of medical devices in hospitals, and increasing healthcare expenditure. Asia Pacific is expected to be the fastest growing market owing to increase in environmental pollution, high incidence of asthma & chronic obstructive pulmonary disease and large patient pool. Moreover, Awareness regarding prevention of hospital acquired infection, pneumonia and quality control measures taken by hospitals for control of nosocomial infection favour the growth of this market. Increasing ageing population and incidence of infectious disease too contribute for the growth of this market in Asia Pacific. On the other hand, the Middle East & Africa region are likely to have a limited but steady growth in the market.
Key Players for global wireless health and fitness devices market
Some of the key players for the global Ventilator-associated pneumonia market Merck & Co., Inc. (U.S.), Adenium Biotech ApS (Denmark), AstraZeneca (UK), MedImmune (US), Nabriva Therapeutics AG (Austria) and other.